乳腺癌组织c—met和HER-2表达与临床病理因素相关性分析

目的：检测乳腺癌组织c-met和HER_2表达状况，分析c-met和HER-2表达的相关性，以及c—met和HER-2表达与临床病理及相关分子生物学信息的相关性。方法：回顾性分析临沂市人民医院2005-06-10～2012-02—20乳腺癌患者临床和病理资料106例，采用免疫组织化学染色方法测定c-met及HER_2基因表达，分析c—met与HER-2表达相关性及其与各临床病理指标的相关性。结果：106例乳腺癌患者中，c-met阳性表达率为64．15％（68／106），HER-2为50．94％（54／106），ER为59．43％（63／106），PR为50．00％（53／106）。HER-2基因表达与乳腺癌患者腋窝淋巴结转移（P=0．001）和肿瘤临床分期（P〈0．001）相关；c-met基因表达与乳腺癌患者腋窝淋巴结转移（P=0．004）及肿瘤临床分期（P=0．001）相关。两者表达与肿瘤直径以夏ER和PR表达差异无统计学意义。HER-2与c—met表达之间无相关性，r=0．071，P=0．172。结论：联合检测c-met及HER_2基因对乳腺癌的淋巴结转移、预后判断及指导临床治疗具有十分重要的意义。

Correlation between the expression of c-met and HER-2 in breast cancer tissues and clinical pathological factors

OBJECTIVE：To detect the expression of c-met and HER-2 gene in breast cancer,and analyze the correla- tion between c-met and HER-2 expression and clinical pathology and molecular biology information. METHODS： The clini- cal and pathological data of 106 cases of breast cancer who were treated in Linyi People＇s Hospital from 2005-06-10 to 2012-02-20 was analysed retrospectively. The c-met gene and HER-2 gene were detected by immunohistochemistry meth- od. The correlation between c-met and HER-2 expression and correlation between clinical pathological factors were ana- lyzed. RESULTS： Positive expression rates of c-met and HER-2 in 106 cases of breast cancer tissue were 64. 15% （68/106） and 50. 94%（54/106） ;Positive expression rates of ER and PR were 59.43% （63/106） and 50.00% （53/106）. The expressions of HER-2 gene had correlation with the axilla lymph node metastasis（P=0. 001） and tumor clinical stag- ing（P〈0. 001）. The expressions of c-met gene had correlation with the axilla lymph node metastasis（P= 0. 004）and tumor clinical staging（P=0. 001）. The expression had no correlation with the tumor diameter and the estrogen receptor and progesterone receptor expression rate. There was no correlation between the expression of HER-2 gene and c-met gene （r=0. 071 ,P=0. 172）. CONCLUSION： Combined detection of c-met and HER-2 gene are of great importance in the pre- dicting the lymph node metastasis, prognosis judgement and clinical comprehensive treatment performation.